AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Misdirected immune response causes more severe illness second time around.

Vaccine Weekly

| July 09, 2003 | COPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2003 JUL 9 - (NewsRx.com & NewsRx.net) -- While some diseases leave the patient with immunity against future attacks, people with dengue fever get sicker the second time around.

Scientists now believe they know why, and their finding may help lead to ways to fight the dangerous mosquito-borne illness.

The problem is "original antigenic sin" on the part of the immune system, according to a team led by Gavin Screaton of the MRC Human Immunology Unit at Weatherall Institute of Molecular Medicine at John Radcliffe Hospital in Oxford, England. Antigens battle diseases invading the body.

There are four subtypes of dengue, and people infected with the disease mount an immune response to fight off the version that infects them. If a patient later acquires a different subtype, however, the immune system mounts an attack directed at the original form of the disease, the researchers found in a study of volunteers in Thailand.

That means they produce immune cells that are less effective against the new form, which can then attack the victim more strongly, the team reports in a paper in the July 2003 issue of the journal Nature Medicine. This misdirected immune response barely fights off the new infection. What's more, some immune cells seem to self-destruct, exacerbating the problem.

Dengue fever causes severe headaches, fever, and rashes. The more serious dengue hemorrhagic fever has a fatality rate of 5%, according to the U.S. Centers for Disease Control and Prevention. The virus is estimated to affect as many as 50 million people annually in tropical areas and kill 12,000 or so. No vaccine or specific treatment has been found.

Having the body respond to the wrong form of the dengue virus complicates the process of developing a vaccine. That's because a vaccine uses a dead or weakened virus to mimic an infection, so the body will recognize the ...

Related articles from newspapers, magazines, journals, and more
The Immune Response Corporation Evaluates a Second-Generation HIV Vaccine...
Press release article from: Business Wire July 9, 2003 700+ words
...BUSINESS WIRE)--July 9, 2003 The Immune Response Corporation (Nasdaq:IMNR) and...HYBN.OB) today announced that The Immune Response Corporation is conducting preclinical...generation vaccine would be based on The Immune Response Corporation's whole-killed HIV...
The Immune Response Corporation Initiates a Preclinical Development Program...
Press release article from: PR Newswire November 3, 2003 700+ words
The Immune Response Corporation announced today that...BULLETIN BOARD: HYBN) to enhance the immune response to a vaccine antigen, with the...Phase II clinical trials by The Immune Response Corporation for the treatment of...
Immune Response Stock Dips After Study.(securities information)(Brief...
Magazine article from: San Diego Business Journal WEBB, MARION November 13, 2000 700+ words
Shares of Immune Response Corp. continued to hover in the...expectations. "The issue is, (Immune Response) had a high-risk drug and did...Remune. McCamant, however, said Immune Response has made a mistake by alienating...
Immune Response Pins Hopes on Study Results.(Brief Article)
Magazine article from: San Diego Business Journal WEBB, MARION September 10, 2001 700+ words
Officials at Immune Response Corp. said they will rely primarily...however, raised concerns whether Immune Response will be able to convince regulators...other data (to get approved)." Immune Response said Aug. 30 it will not pursue...
The Immune Response Corporation Licenses Hybridon's 2nd-Generation CpG DNA...
Press release article from: PR Newswire October 9, 2003 700+ words
The Immune Response Corporation and Hybridon, Inc...Phase II clinical trials by The Immune Response Corporation, plus AMPLIVAX, Hybridon...adjuvant designed to enhance the immune response to a vaccine antigen. The Immune...
Schering-Plough and Immune Response in Agreement to Develop Hepatitis Gene...
Press release article from: PR Newswire July 9, 1998 700+ words
...Corporation (NYSE: SGP) and The Immune Response Corporation (Nasdaq: IMNR) today...collaboration and option agreement to combine Immune Response's proprietary GeneDrug(TM) gene...gene therapy technology developed by Immune Response in conjunction with type-1 interferon...
The Immune Response Corporation and NovaRx Corporation Announce Revision of...
Press release article from: PR Newswire September 8, 2004 700+ words
The Immune Response Corporation , a biopharmaceutical...agreement to transfer all of The Immune Response Corporation's in-licensed development...addition, NovaRx agreed to pay The Immune Response Corporation the total sum of...
The Immune Response Corporation Progress Report at the NYSSA 7th Annual Health...
Press release article from: PR Newswire November 18, 2003 700+ words
The Immune Response Corporation announced today that...discussing the revitalization that The Immune Response Corporation has achieved during...2003 have been important for The Immune Response Corporation as we implemented our...
For more facts and information, see all results

Source: HighBeam Research, Misdirected immune response causes more severe illness second time...

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA